secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001739104-25-000052
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q2 rev +5% to $1.24B, raises FY2025 outlook; net leverage target improved
--------------------------------------------------------------------------------

- Q2 revenue $1,241M (+5% reported, +8% organic CC); adjusted EPS $0.26 vs $0.30 prior year.
- FY2025 revenue guidance raised to $4,570-4,620M; adjusted EPS raised to $0.85-0.91.
- Full-year innovation revenue target increased by $60M to $720-800M; Credelio Quattro and Experior drive growth.
- Net leverage ratio improved to 4.0x at Q2 end; year-end target tightened to 3.8x-4.1x.
- Robert VanHimbergen appointed EVP and CFO effective July 7, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000173910425000052/0001739104-25-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000173910425000052/elan-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001739104-25-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer